The case for & against
Bull & Bear analysis
Neuronetics, Inc. (NASDAQ: STIM) is a leading provider of innovative non-invasive therapies for mental health, particularly focusing on treatment-resistant depression through its NeuroStar TMS system. Following its acquisition of Greenbrook TMS, Neuronetics has expanded its operational footprint with a national clinic network dedicated to improving access to critical mental health treatments. The company's strategy revolves around leveraging its clinic operations to optimize market share and enhance service offerings amidst evolving patient needs and increasing competition in the mental health sector.
Bull says
- ↑Q1 revenue reached $34.5M (+8% YoY), with U.S. clinic sales up 15%.
- ↑Cost measures to yield $2.5–3M annual savings from Q3, cash at $19M.
- ↑Addressable U.S. market ~4M treatment-resistant depression patients.
- ↑Potential psilocybin therapy approval could broaden product portfolio.
- ↑High institutional backing and positive analyst revisions indicate confidence.
Bear says
- ↓Gross margin fell to 46.9% vs. 49.2% YoY, pressuring earnings.
- ↓Under DOJ billing probe pre-acquisition, raising compliance costs risk.
- ↓Revenue relies on variable third-party reimbursements, impacting cash flows.
- ↓Weather disruptions caused volatile TMS session volumes and revenues.
- ↓Projected cash burn of $4–8M strains liquidity beyond $19M cash.
- ↓Weak profitability and elevated leverage risk challenge long-term viability.
Investment themes with STIM
Clinical instruments and devices powering patient care
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- So I think that was one of the reasons that we saw the impact within Greenbrook. On the Neurostar side, we think that we saw some of the same kind of impact from weather.
- we were actually up low single digits. on absolute utilization within our Neurostar business as far as treatment sessions were concerned.
- overall, you know, I would say the business held up quite well in spite of the weather.
Bear points
- U.S. treatment session revenue was $9.1 million, a decrease of 5%.
- The decrease in gross margin is a result of revenue mix with clinic revenues representing a higher portion of our overall revenues.